Select clinical outcomes and adverse events reported with BR compared with R-CHOP/R-CVP in untreated patients with indolent and mantle cell lymphoma
| Efficacy . | ||
|---|---|---|
| . | BR . | R-CHOP/R-CVP . |
| Overall response rate | 97% | 91% |
| Complete response | 31% | 25% |
| Partial pesponse | 65% | 66% |
| Efficacy . | ||
|---|---|---|
| . | BR . | R-CHOP/R-CVP . |
| Overall response rate | 97% | 91% |
| Complete response | 31% | 25% |
| Partial pesponse | 65% | 66% |
| Toxicity . | |||
|---|---|---|---|
| . | BR . | R-CHOP . | R-CVP . |
| Nausea | 63% | 58% | 39% |
| Opportunistic infection | 10-12% | 7% | 9% |
| Rash | 20-24% | 12% | 16% |
| Neuropathy | 9-14% | 44% | 47% |
| Alopecia | 3-4% | 51% | 21% |
| Neutropenia (Gr3+) | 39-49% | 87% | 56% |
| Lymphopenia (Gr3+) | 61-63% | 33% | 28% |
| Platelets (Gr3+) | 5-10% | 12% | 2% |
| Toxicity . | |||
|---|---|---|---|
| . | BR . | R-CHOP . | R-CVP . |
| Nausea | 63% | 58% | 39% |
| Opportunistic infection | 10-12% | 7% | 9% |
| Rash | 20-24% | 12% | 16% |
| Neuropathy | 9-14% | 44% | 47% |
| Alopecia | 3-4% | 51% | 21% |
| Neutropenia (Gr3+) | 39-49% | 87% | 56% |
| Lymphopenia (Gr3+) | 61-63% | 33% | 28% |
| Platelets (Gr3+) | 5-10% | 12% | 2% |
Adapted from Tables 2 and 4 in the article by Flinn et al that begins on page 2944.